Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in early patient studies. Ongoing research https://telebookmarks.com/story11955369/retatrutide-emerging-research-and-projected-therapeutic-uses